NEW YORK– Cleerly, the company creating a new standard of care for heart disease, announced it has appointed Joseph “Joe” Jasser, MD, as chief of value based care. In this role, Dr. Jasser will be responsible for developing and executing the initial business plan and go-to-market strategy for the value-based care client segment. He will also lead the commercial and client services teams for Cleerly’s Value Based Care vertical, and will report to Jim Hartman, chief revenue officer of Cleerly.
“I’m very excited to have Joe join us on our mission to create a world without heart attacks,” Hartman said. “His knowledge of and passion for designing tailored solutions to provide an excellent patient experience, while also optimizing the clinical and financial outcomes of a value-based care model for clients, makes him a natural fit for the Cleerly team. Joe has impressive experience as a builder of highly successful value-based care models – whether he’s working in a health system, health plan or business-to-business organization within the healthcare industry.”
Prior to joining Cleerly, Dr. Jasser was chief medical officer of Vesta Healthcare and previously, he was the chief medical officer of bclinical, PLLC where he provided clinical consultative services for clinical delivery organizations and medical groups. He has also served as the chief medical officer and executive vice president of complex care management at Signify Health and was the president of care delivery for Humana, Inc. Additionally, Dr. Jasser served as the president and CEO of Dignity Health Medical Foundation and held roles at Cigna-HealthSpring, CIGNA and Concentra.
Dr. Jasser earned his Bachelor of Science degree from The Ohio State University, his medical degree from The Ohio State University College of Medicine and an Executive Master of Business Administration from Washington State University. He completed his residency at Summa Health System and is board certified in internal medicine.
“I’m excited about what Cleerly can and will do for cardiovascular disease; it’s disruptive and revolutionary,” Dr. Jasser said. “I look forward to building Cleerly’s value-based care client segment with a variety of solutions for health plans and providers that offer a new, improved standard of cardiovascular care to patients.”
This appointment comes after Cleerly’s recently announced Series C funding round of $223 million led by T. Rowe Price and Fidelity.
